3737 — Zhongzhi Pharmaceutical Holdings Income Statement
0.000.00%
- HK$1.08bn
- HK$1.09bn
- CNY2.05bn
- 88
- 86
- 29
- 82
Annual income statement for Zhongzhi Pharmaceutical Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,342 | 1,604 | 1,747 | 1,826 | 2,050 |
Cost of Revenue | |||||
Gross Profit | 833 | 991 | 1,064 | 1,070 | 1,221 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,182 | 1,431 | 1,678 | 1,689 | 1,834 |
Operating Profit | 160 | 172 | 68.9 | 137 | 215 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 156 | 167 | 61.8 | 131 | 208 |
Provision for Income Taxes | |||||
Net Income After Taxes | 115 | 139 | 52.4 | 107 | 164 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 115 | 139 | 52.1 | 106 | 163 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 115 | 139 | 52.1 | 106 | 163 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.137 | 0.167 | 0.062 | 0.125 | 0.192 |
Dividends per Share | |||||
Special Dividends per Share |